Search
Repligen Corp
RGENAdd to Watchlist
136.630USD
-0.370-0.27%
Market hours （ET）Quotes delayed by 15 min
7.70BMarket Cap
149.57P/E TTM
More Details of Repligen Corp Company
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Repligen Corp Info
Ticker SymbolRGEN
Company nameRepligen Corp
IPO dateApr 29, 1986
CEOLoeillot (Olivier)
Number of employees1778
Security typeOrdinary Share
Fiscal year-endApr 29
AddressBuilding 1, Suite 100
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02453
Phone17814499560
Websitehttps://www.repligen.com/
Ticker SymbolRGEN
IPO dateApr 29, 1986
CEOLoeillot (Olivier)
Company Executives of Repligen Corp
Name
Name/Position
Position
Shareholding
Change
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
92.82K
+1.07%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
40.05K
+8.56%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
9.42K
-28.60%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
5.44K
+18.30%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
5.01K
+19.84%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.22K
-155.54%
Mr. Tony John Hunt
Mr. Tony John Hunt
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Ms. Carrie Eglinton Manner
Ms. Carrie Eglinton Manner
Independent Director
Independent Director
--
--
Mr. James R. Bylund
Mr. James R. Bylund
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Konstantin Konstantinov, Ph.D.
Dr. Konstantin Konstantinov, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Karen A. Dawes
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
92.82K
+1.07%
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
40.05K
+8.56%
Mr. Ralf Kuriyel
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
9.42K
-28.60%
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Independent Director
5.44K
+18.30%
Mr. Rohin Mhatre, Ph.D.
Mr. Rohin Mhatre, Ph.D.
Independent Director
Independent Director
5.01K
+19.84%
Mr. Olivier Loeillot
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.22K
-155.54%
FAQs
Who are the top five shareholders of Repligen Corp?
The top five shareholders of Repligen Corp are: Ms. Karen A. Dawes
How many institutions hold shares of Repligen Corp (RGEN)?
As of 2026Q1, 1067 institutions hold shares of Repligen Corp, with a combined market value of approximately 65.93M, accounting for 116.89% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2643397.00.
What is the biggest source of revenue for Repligen Corp?
In 2026Q1, the Product revenue - Filtration products business generated the highest revenue for Repligen Corp, amounting to 402.79M and accounting for 54.58% of total revenue.
